Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.

Aljumah AA, Abaalkhail F, Al-Ashgar H, Assiri A, Babatin M, Al Faleh F, Alghamdi A, Al-Hakeem R, Hashim A, Alqutub A, Razavi H, Sanai FM, Al-Swat K, Schmelzer J, Altraif I.

Saudi J Gastroenterol. 2016 Jul-Aug;22(4):269-81. doi: 10.4103/1319-3767.187609.

2.

Influence of cytokine and cytokine receptor gene polymorphisms on the degree of liver damage in patients with chronic hepatitis C.

Moreira ST, Silva GF, de Moraes CF, Grotto RM, de Moura Campos Pardini MI, Bicalho Mda G, Moliterno RA.

Meta Gene. 2016 Apr 21;9:90-6. doi: 10.1016/j.mgene.2016.04.003. eCollection 2016 Sep.

3.

KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver..

Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Epub 2016 Mar 28. Review. No abstract available.

4.

Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.

Simon TG, Bonilla H, Yan P, Chung RT, Butt AA.

Hepatology. 2016 Jul;64(1):47-57. doi: 10.1002/hep.28506. Epub 2016 Mar 25.

PMID:
26891205
5.

Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus.

Douglas DN, Pu CH, Lewis JT, Bhat R, Anwar-Mohamed A, Logan M, Lund G, Addison WR, Lehner R, Kneteman NM.

J Biol Chem. 2016 Jan 22;291(4):1974-90. doi: 10.1074/jbc.M115.674861. Epub 2015 Dec 1.

6.

Era of direct acting antivirals in chronic hepatitis C: Who will benefit?

Fung J.

World J Hepatol. 2015 Oct 28;7(24):2543-50. doi: 10.4254/wjh.v7.i24.2543. Review.

7.

Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission.

Daw MA, El-Bouzedi A, Dau AA.

BMC Res Notes. 2015 Aug 21;8:367. doi: 10.1186/s13104-015-1310-x.

8.

Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.

Pouliot JJ, Thomson M, Xie M, Horton J, Johnson J, Krull D, Mathis A, Morikawa Y, Parks D, Peterson R, Shimada T, Thomas E, Vamathevan J, Van Horn S, Xiong Z, Hamatake R, Peat AJ.

Antimicrob Agents Chemother. 2015 Oct;59(10):6539-50. doi: 10.1128/AAC.00813-15. Epub 2015 Aug 10.

9.

Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Simon TG, Butt AA.

World J Gastroenterol. 2015 Jul 21;21(27):8293-303. doi: 10.3748/wjg.v21.i27.8293. Review.

10.

Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.

Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Bekki S, Kugiyama Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Ichikawa T, Nakao K, Yatsuhashi H.

PLoS One. 2015 Jun 12;10(6):e0129053. doi: 10.1371/journal.pone.0129053. eCollection 2015.

11.

A public health approach to hepatitis C control in low- and middle-income countries.

Suthar AB, Harries AD.

PLoS Med. 2015 Mar 10;12(3):e1001795. doi: 10.1371/journal.pmed.1001795. eCollection 2015 Mar.

12.

Human Interferon Regulatory Factor 2 Gene Expression is Induced in Chronic Hepatitis C Virus Infection-A Possible Mode of Viral Persistence.

Mukherjee RM, Bansode B, Gangwal P, Jakkampudi A, Reddy PB, Rao PN, Gupta R, Nageshwar Reddy D.

J Clin Exp Hepatol. 2012 Mar;2(1):27-34. doi: 10.1016/S0973-6883(12)60080-2. Epub 2012 Apr 12.

13.

Interleukin 28B Polymorphisms and Hepatitis C-Translating the Association into Clinical Decision Making.

Puri CP.

J Clin Exp Hepatol. 2011 Jun;1(1):27-33. doi: 10.1016/S0973-6883(11)60115-1. Epub 2011 Aug 26.

14.

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study.

Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M.

Hepat Mon. 2014 Oct 1;14(10):e22649. doi: 10.5812/hepatmon.22649. eCollection 2014 Oct.

15.

Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.

Feng B, Zhang W, Luo BF, Song GJ, Wang J, Jin Q, Qin H, Wei L.

World J Gastroenterol. 2014 Nov 7;20(41):15387-97. doi: 10.3748/wjg.v20.i41.15387. Review.

16.

Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis.

Luo YQ, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C.

J Zhejiang Univ Sci B. 2014 Oct;15(10):900-6. doi: 10.1631/jzus.B1400073. Review.

17.

Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.

Liu M, Tuttle M, Gao M, Lemm JA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7416-23. doi: 10.1128/AAC.03851-14. Epub 2014 Sep 29.

18.

Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.

Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, Bruce D, Cohen AJ, Bohorquez HE, Carmody I, Loss G, Balart LA, Wu T, Dash S.

PLoS One. 2014 Sep 29;9(9):e108616. doi: 10.1371/journal.pone.0108616. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e114456. Behorquez, Humberto E [corrected to Bohorquez, Humberto E].

19.

Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Clausen LN, Lundbo LF, Benfield T.

World J Gastroenterol. 2014 Sep 14;20(34):12132-43. doi: 10.3748/wjg.v20.i34.12132. Review.

20.

Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C.

Simon TG, King LY, Zheng H, Chung RT.

J Hepatol. 2015 Jan;62(1):18-23. doi: 10.1016/j.jhep.2014.08.013. Epub 2014 Aug 15.

Supplemental Content

Support Center